CY1115714T1 - Συνθεσεις και μεθοδοι για τη θεραπεια της πολλαπλης σκληρυνσης - Google Patents
Συνθεσεις και μεθοδοι για τη θεραπεια της πολλαπλης σκληρυνσηςInfo
- Publication number
- CY1115714T1 CY1115714T1 CY20141100908T CY141100908T CY1115714T1 CY 1115714 T1 CY1115714 T1 CY 1115714T1 CY 20141100908 T CY20141100908 T CY 20141100908T CY 141100908 T CY141100908 T CY 141100908T CY 1115714 T1 CY1115714 T1 CY 1115714T1
- Authority
- CY
- Cyprus
- Prior art keywords
- treatment
- compositions
- methods
- multiple sclerosis
- relates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Fodder In General (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Photographic Developing Apparatuses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ577731A NZ577731A (en) | 2009-06-16 | 2009-06-16 | Compositions and methods for treatment of multiple sclerosis |
| EP10789788.6A EP2442832B1 (en) | 2009-06-16 | 2010-06-16 | Compositions and methods for treatment of multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1115714T1 true CY1115714T1 (el) | 2017-01-25 |
Family
ID=42646236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20141100908T CY1115714T1 (el) | 2009-06-16 | 2014-11-03 | Συνθεσεις και μεθοδοι για τη θεραπεια της πολλαπλης σκληρυνσης |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8389479B2 (https=) |
| EP (1) | EP2442832B1 (https=) |
| JP (1) | JP5646617B2 (https=) |
| CN (1) | CN102458476B (https=) |
| AU (1) | AU2010260585B2 (https=) |
| BR (1) | BRPI1009606A2 (https=) |
| CA (1) | CA2688766C (https=) |
| CY (1) | CY1115714T1 (https=) |
| DK (1) | DK2442832T3 (https=) |
| ES (1) | ES2521565T3 (https=) |
| HR (1) | HRP20141035T1 (https=) |
| IL (1) | IL216993A (https=) |
| IN (1) | IN2012DN00167A (https=) |
| MX (1) | MX2011013661A (https=) |
| NZ (1) | NZ577731A (https=) |
| PL (1) | PL2442832T3 (https=) |
| PT (1) | PT2442832E (https=) |
| SI (1) | SI2442832T1 (https=) |
| SM (1) | SMT201400165B (https=) |
| WO (1) | WO2010147484A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009123480A1 (en) * | 2008-04-01 | 2009-10-08 | Virionyx Corporation Ltd | Anti-infective agents and uses thereof |
| HUE050713T2 (hu) * | 2010-10-25 | 2020-12-28 | Biogen Ma Inc | Módszerek az ALFA-4 integrin aktivitás eltéréseinek meghatározásához, a sVCAM ÉS/VAGY sMAdCAM szintek egymáshoz viszonyításával |
| UY35790A (es) * | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| WO2017059486A1 (en) * | 2015-10-06 | 2017-04-13 | Innate Immunotherapeutics Limited | Compositions and methods for the treatment of epilepsy |
| CA2926507A1 (en) * | 2015-10-06 | 2017-04-06 | Innate Immunotherapeutics Limited | Compositions and methods for protection and/or repair of the nervous system |
| WO2017070731A1 (en) * | 2015-10-28 | 2017-05-04 | Innate Immunotherapeutics Limited | Compositions and methods for the treatment of alzheimer's disease |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| HUE071047T2 (hu) | 2016-08-31 | 2025-07-28 | Mapi Pharma Ltd | Glatiramer-acetátot tartalmazó depórendszerek |
| CN110382052A (zh) | 2017-03-26 | 2019-10-25 | Mapi医药公司 | 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统 |
| CA3099946A1 (en) * | 2018-05-18 | 2019-11-21 | Universite Laval | Use of nod2 agonist for the treatment, prophylaxis and/or delay of the onset of multiple sclerosis and alzheimer's disease |
| WO2020010221A1 (en) * | 2018-07-03 | 2020-01-09 | University Of Florida Research Foundation, Inc. | Microparticle systems and their use for the treatment of multiple sclerosis |
| US20230190570A1 (en) * | 2020-06-22 | 2023-06-22 | Otivio As | Methods for treating spasticity using anti-spasmodic compositions and negative pressure therapy |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1327896C (zh) * | 1996-10-10 | 2007-07-25 | 探针国际公司 | 治疗病毒感染的组合物及方法 |
| JP2008505130A (ja) * | 2004-07-01 | 2008-02-21 | ケベンハウンス・ウニヴェルジテート | レプトスピラ属感染の治療による多発性硬化症の治療及び予防方法 |
| US8603978B2 (en) * | 2006-12-01 | 2013-12-10 | The United States of America, as represented by the Secretary, Department of Health and Humand Services | Use of muramyl dipeptide (MDP) for treating inflammation |
| JP2008251608A (ja) | 2007-03-29 | 2008-10-16 | Casio Comput Co Ltd | 半導体装置およびその製造方法 |
| WO2008150181A1 (en) | 2007-06-05 | 2008-12-11 | Innate Therapeutics Limited | Compositions and methods for treating anthrax exposure associated conditions |
| WO2008150182A1 (en) | 2007-06-05 | 2008-12-11 | Innate Therapeutics Limited | Compositions and methods for treatment of anthrax |
-
2009
- 2009-06-16 NZ NZ577731A patent/NZ577731A/en not_active IP Right Cessation
- 2009-12-16 US US12/639,733 patent/US8389479B2/en not_active Expired - Fee Related
- 2009-12-17 CA CA2688766A patent/CA2688766C/en not_active Expired - Fee Related
-
2010
- 2010-01-16 BR BRPI1009606A patent/BRPI1009606A2/pt not_active Application Discontinuation
- 2010-01-16 CN CN201080026791.5A patent/CN102458476B/zh not_active Expired - Fee Related
- 2010-06-16 SI SI201030779T patent/SI2442832T1/sl unknown
- 2010-06-16 PL PL10789788T patent/PL2442832T3/pl unknown
- 2010-06-16 WO PCT/NZ2010/000112 patent/WO2010147484A1/en not_active Ceased
- 2010-06-16 DK DK10789788.6T patent/DK2442832T3/da active
- 2010-06-16 HR HRP20141035AT patent/HRP20141035T1/hr unknown
- 2010-06-16 PT PT107897886T patent/PT2442832E/pt unknown
- 2010-06-16 IN IN167DEN2012 patent/IN2012DN00167A/en unknown
- 2010-06-16 EP EP10789788.6A patent/EP2442832B1/en active Active
- 2010-06-16 JP JP2012516022A patent/JP5646617B2/ja not_active Expired - Fee Related
- 2010-06-16 MX MX2011013661A patent/MX2011013661A/es active IP Right Grant
- 2010-06-16 AU AU2010260585A patent/AU2010260585B2/en not_active Ceased
- 2010-06-16 ES ES10789788.6T patent/ES2521565T3/es active Active
-
2011
- 2011-12-15 IL IL216993A patent/IL216993A/en not_active IP Right Cessation
-
2014
- 2014-11-03 CY CY20141100908T patent/CY1115714T1/el unknown
- 2014-11-04 SM SM201400165T patent/SMT201400165B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2442832A4 (en) | 2013-07-03 |
| IN2012DN00167A (https=) | 2015-04-17 |
| US20100317589A1 (en) | 2010-12-16 |
| BRPI1009606A2 (pt) | 2016-10-11 |
| HK1167101A1 (en) | 2013-02-01 |
| CA2688766C (en) | 2015-06-30 |
| MX2011013661A (es) | 2012-05-22 |
| AU2010260585B2 (en) | 2013-02-21 |
| PT2442832E (pt) | 2014-11-11 |
| PL2442832T3 (pl) | 2015-01-30 |
| WO2010147484A8 (en) | 2012-07-19 |
| JP2012530132A (ja) | 2012-11-29 |
| AU2010260585A1 (en) | 2012-01-19 |
| SMT201400165B (it) | 2015-01-15 |
| CA2688766A1 (en) | 2010-12-16 |
| DK2442832T3 (da) | 2014-11-10 |
| ES2521565T3 (es) | 2014-11-12 |
| HRP20141035T1 (hr) | 2014-12-19 |
| EP2442832A1 (en) | 2012-04-25 |
| NZ577731A (en) | 2010-08-27 |
| EP2442832B1 (en) | 2014-08-06 |
| AU2010260585A8 (en) | 2012-06-14 |
| JP5646617B2 (ja) | 2014-12-24 |
| CN102458476B (zh) | 2014-08-20 |
| WO2010147484A1 (en) | 2010-12-23 |
| IL216993A (en) | 2016-03-31 |
| CN102458476A (zh) | 2012-05-16 |
| IL216993A0 (en) | 2012-02-29 |
| SI2442832T1 (sl) | 2014-12-31 |
| US8389479B2 (en) | 2013-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1115714T1 (el) | Συνθεσεις και μεθοδοι για τη θεραπεια της πολλαπλης σκληρυνσης | |
| CY1123052T1 (el) | Συνθεσεις και μεθοδοι σχετικες με παραλλαγες της πρωτεϊνες α (spa) | |
| CY1123470T1 (el) | Αναστολεις ιβατ για την αγωγη ηπατοπαθειων | |
| CY1125705T1 (el) | Πρωτεϊνες προσδεσης καλλικρεϊνης πλασματος | |
| CY1119892T1 (el) | Φορεις και αλληλουχιες για την αγωγη ασθενειων | |
| CY1121742T1 (el) | Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων | |
| CY1116435T1 (el) | Ενωσεις βορονικου εστερα και φαρμακευτικες συνθεσεις αυτων | |
| CY1119255T1 (el) | Μεθοδος, σωληναριο και συσκευη για την παρασκευη συνθεσης επουλωσης πληγης | |
| CY1116578T1 (el) | Αναστολεις της bromodomain και χρησεις αυτων | |
| UA106586C2 (uk) | Анти-cd79b антитіла, і імунокон'югати та способи їх застосування | |
| EA201170212A1 (ru) | Охлаждение и обработка материалов | |
| EA201101521A1 (ru) | Способы лечения онкологических заболеваний, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния | |
| MX346450B (es) | Composiciones y métodos para el tratamiento de la enfermedad celíaca. | |
| CY1117678T1 (el) | Ενωσεις αναστολεων μεταλλοενζυμου | |
| CY1120557T1 (el) | Μορια δεσμευσης anti-pseudomonas psl και χρησεις αυτων | |
| MY159396A (en) | Compositions and methods for antibodies targeting complement protein c5 | |
| HUE036780T2 (hu) | Új kompozíciók és eljárások immunológiai vonatkozású betegségek kezelésére | |
| EP2405918A4 (en) | PREBIOTIC OLIGOSACCHARIDE | |
| CY1118813T1 (el) | Φαρμακευτικες συνθεσεις συν-κρυσταλλων τραμαδολης και κοξιμπων | |
| CY1118710T1 (el) | Συνθεσεις για την θεραπεια της πολλαπλης σκληρυνσης | |
| EP2294192A4 (en) | COMPOSITIONS AND METHODS OF TREATMENT AND VACCINATION AGAINST DENGUE VIRUS (DV) | |
| MA32544B1 (fr) | Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique | |
| BR112013003722A2 (pt) | produtos para cuidado e métodos de uso e fabricação dos mesmos | |
| ITTO20110641A1 (it) | Composizioni farmaceutiche e metodi di trattamento | |
| BR112012019844A2 (pt) | metodos e composições para melhorar a resistência mecânica dos dentes |